SCIENCE

FESPIXON® Cream

 

  • Brand Name
FESPIXON® Cream
  • Indications
Diabetic Foot Ulcers (DFU)
  • Mechanism of Action
  • Inhibits inflammation
  • Regulates the generation of collagen
  • Promotes the regeneration of damaged cells
  • Promotes the proliferation of human keratinocytes
  • Reduce inflammatory M1 macrophages, stimulate adipose precursor cells to secrete GCSF and CXCL3, and increase repairing M2a/M2c macrophages, thereby promote complete wound healing. The mechanism of action studies can be referred to JID Innovations (2022).
  • Taiwan FDA Approval Number

060827

  • Singapore HSA Approval Number
SIN16683P
  • Malaysia NPRA Approval Number 
MAL23076025B
  • China NMPA Approval Number 
ZC20230001 (Approved generic name: Xianglei Tangzu Gao)
  • Indonesia BPOM Approval Number 
TI247049901
  • Research Publication/ Abstract
More Infromation

You are encouraged to report negative side effects of prescription drugs to:
Phone: 0800-258-688
Mail: PV.PMS@onenessbio.com.tw

Prescription medications must be used only under the direction of a licensed physician. If you have any health concerns, please seek medical advice from a qualified healthcare provider. Find the closest hospital for medical care.

 

Package Insert Download

 

  • Brand Name
FESPIXON® Cream
  • Indications
Diabetic Foot Ulcers (DFU)
  • Mechanism of Action
  • Inhibits inflammation
  • Regulates the generation of collagen
  • Promotes the regeneration of damaged cells
  • Promotes the proliferation of human keratinocytes
  • Reduce inflammatory M1 macrophages, stimulate adipose precursor cells to secrete GCSF and CXCL3, and increase repairing M2a/M2c macrophages, thereby promote complete wound healing. The mechanism of action studies can be referred to JID Innovations (2022).
  • Taiwan FDA Approval Number

060827

  • Singapore HSA Approval Number

SIN16683P

  • Malaysia NPRA Approval Number

MAL23076025B

  • China NMPA Approval Number 
  • Indonesia BPOM Approval Number 

TI247049901

  • Research Publication/ Abstract

Click Here

 

You are encouraged to report negative side effects of prescription drugs to:
Phone: 0800-258-688
Mail:
PV.PMS@onenessbio.com.tw

Prescription medications must be used only under the direction of a licensed physician. If you have any health concerns, please seek medical advice from a qualified healthcare provider. Find the closest hospital for medical care.


Package Insert Download

Mechanism of Action

Novel Mechanism Promotes Healing by Regulating M1/M2 Macrophages
and Rebalancing the Wound Microenvironment

Inhibit pro-inflammatory M1 φ and stimulate adipose precursor cells to secrete GCSF and CXCL3 to increase repairing M2a/M2c φ

Reference: Restoring Pro-healing/remodeling-associated M2a/c Macrophages using ON101 Accelerates Diabetic Wound Healing, JID Innovations (2022);2:100138, doi: https://doi.org/10.1016/j.xjidi.2022.100138.

 

Superior Efficacy to Current Standard Care

 

Incidence of Complete Healing - Full Analysis Set

FESPIXON® group achieved significant efficacy vs standard care (AQUACEL® Hydrofiber®) group (p=0.0001)

The Cumulative Rate of Complete Healing

The healing trend of FESPIXON® remained steady and robust at each observation time point.  

Incidence of Complete Healing - Full Analysis Set

FESPIXON® group achieved significant efficacy vs standard care (AQUACEL® Hydrofbier®) group (p=0.0001)

The Cumulative Rate of Complete Healing

The healing trend of FESPIXON® remained steady and robust at each observation time point.  

Reference: Effect of a Novel Macrophage-Regulating Drug on Wound Healing in Patients With Diabetic Foot Ulcers, JAMA Netw Open. 2021;4(9):e2122607, doi:10.1001/jamanetworkopen.2021.22607.

 

/* 以上是表格-计算机版RWD */

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services.
By clicking ‘Accept’ you are indicating your consent for us to place these cookies.
For more information, please read our Cookie Policy and Website Privacy Policy.
Accept